The Fly | PHRRF

Over a week ago

Psychedelic: Enveric announces EB-003 manufacturing milestones

Oct 2, 11:09 AM

PharmaTher provides update on ketamine development, commercial strategy

PHRRF

Oct 2, 8:12 AM

PharmaTher announces sales of ketamine ANDA

PHRRF

Oct 1, 8:15 AM

PharmaTher provides update following FDA approval of ketamine

PHRRF

Aug 26, 8:07 AM

Psychedelic: atai Life Sciences, Cybin report earnings results

Aug 14, 11:25 AM

PharmaTher issues letter to shareholders

PHRRF

Aug 14, 8:24 AM

PharmaTher announces FDA approval of ketamine product

PHRRF

Aug 11, 9:27 AM

No more stories

Proprietary Microneedle Patch Technology: PharmaTher has developed and is advancing a proprietary microneedle patch (MNP) platform for the transdermal delivery of therapeutics, including psychedelics, offering a potentially superior, non-invasive, and controlled drug delivery method.

Transdermal Ketamine Delivery (KPL-01): Their lead asset, KPL-01, is a ketamine microneedle patch aiming to provide a non-invasive, controlled, and extended-release option for pain and mental health indications, differentiating it from traditional administration routes.

Diversified Psychedelic Pipeline: The company is exploring multiple psychedelic compounds (e.g., psilocybin, DMT) in addition to ketamine, targeting a broader range of neurological and mental health disorders.

Clinical Trial Failure Risk: The success of PharmaTher's drug candidates hinges on positive outcomes in pre-clinical and clinical trials, and a high percentage of drug candidates fail to achieve regulatory approval or market commercialization.

Regulatory Approval Uncertainty Risk: Obtaining necessary regulatory approvals for its novel drug candidates, especially those involving controlled substances like psychedelics, is a complex, lengthy, and highly uncertain process with no guarantee of success.

Capital and Funding Requirements Risk: PharmaTher is a development-stage company that requires substantial capital to fund its research, clinical trials, and operational expenses, and there is no assurance it will be able to raise sufficient funds on acceptable terms to continue its operations.